# Frank W Rockhold

List of Publications by Year
in descending order



| 102 | 8,608 | 218381 | 48187 |
|---|---|---|---|
| papers | citations | 26 h-index | 88 g-index |

| 108 | 108 | 108 | 16560 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The Current Landscape in Biostatistics of Real-World Data and Evidence: Clinical Study Design and Analysis. Statistics in Biopharmaceutical Research, 2023, 15, 29-42. | 0.6 | 19 |
| 2 | The Current Landscape in Biostatistics of Real-World Data and Evidence: Causal Inference Frameworks for Study Design and Analysis. Statistics in Biopharmaceutical Research, 2023, 15, 43-56. | 0.6 | 32 |
| 3 | Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment. Statistics in Biopharmaceutical Research, 2023, 15, 3-13. | 0.6 | 24 |
| 4 | Institutional approaches to preventing questionable research practices. Accountability in Research, 2023, 30, 252-259. | 1.6 | 2 |
| 5 | Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey. JMIR Medical Informatics, 2022, 10, e30363. | 1.3 | 21 |
| 6 | Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet, The, 2022, 399, 461-472. | 6.3 | 69 |
| 7 | Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions â€" proceedings from the CEC Summit 2018. American Heart Journal, 2022, 246, 93-104. | 1.2 | 3 |
| 8 | Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World. Clinical Therapeutics, 2022, 44, 420-437. | 1.1 | 36 |
| 9 | Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIAâ€CKD. Journal of the American Heart Association, 2022, 11, e022003. | 1.6 | 6 |
| 10 | COVID-19 Trials: Who Participates and Who Benefits?. Southern Medical Journal, 2022, 115, 256-261. | 0.3 | 2 |
| 11 | The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE study. Contemporary Clinical Trials, 2022, 115, 106732. | 0.8 | 2 |
| 12 | Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial. Lancet Infectious Diseases, The, 2022, 22, 990-1001. | 4.6 | 16 |
| 13 | Impact of Polyvascular Disease and Diabetes onÂLimb and Cardiovascular Risk in Peripheral Artery Disease. Journal of the American College of Cardiology, 2022, 79, 1781-1783. | 1.2 | 1 |
| 14 | Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. Journal of the American Heart Association, 2022, 11, . | 1.6 | 4 |
| 15 | Myocardial Infarction in the ISCHEMIA Trial. Circulation, 2021, 143, 790-804. | 1.6 | 81 |
| 16 | A randomized, open-label, pragmatic study to assess reliever-triggered inhaled corticosteroid in African American/Black and Hispanic/Latinx adults with asthma: Design and methods of the PREPARE trial. Contemporary Clinical Trials, 2021, 101, 106246. | 0.8 | 14 |
| 17 | Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. International Journal of COPD, 2021, Volume 16, 841-851. | 0.9 | 6 |
| 18 | Effect of COVID-19 on asthma exacerbation. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2896-2899.e1. | 2.0 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nature Communications, 2021, 12, 2349. | 5.8 | 194 |
| 20 | Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. Circulation: Heart Failure, 2021, 14, e008100. | 1.6 | 30 |
| 21 | What can heart failure trialists learn from oncology trialists?. European Heart Journal, 2021, 42, 2373-2383. | 1.0 | 9 |
| 22 | Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial. Vascular Medicine, 2021, 26, 1358863X2110176. | 0.8 | 0 |
| 23 | Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. Journal of the American Heart Association, 2021, 10, e018684. | 1.6 | 13 |
| 24 | Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. Circulation: Cardiovascular Interventions, 2021, 14, e009871. | 1.4 | 2 |
| 25 | Primary and Secondary Outcome Reporting in Randomized Trials. Journal of the American College of Cardiology, 2021, 78, 827-839. | 1.2 | 28 |
| 26 | World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial. Vascular Medicine, 2021, , 1358863X2110386. | 0.8 | 2 |
| 27 | Open Science to Address COVID-19: Sharing Data to Make Our Research Investment Go Further. Therapeutic Innovation and Regulatory Science, 2021, 55, 558-560. | 0.8 | 5 |
| 28 | Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. American Heart Journal, 2020, 220, 51-58. | 1.2 | 8 |
| 29 | Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2020, 13, e009326. | 1.4 | 7 |
| 30 | Cause of Death Among Patients With Peripheral Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006550. | 0.9 | 10 |
| 31 | Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job. Annals of Internal Medicine, 2020, 172, 119. | 2.0 | 18 |
| 32 | CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. American Heart Journal, 2020, 229, 118-120. | 1.2 | 2 |
| 33 | Adaptive trial designs for spinal cord injury clinical trials directed to the central nervous system. Spinal Cord, 2020, 58, 1235-1248. | 0.9 | 17 |
| 34 | Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006512. | 0.9 | 16 |
| 35 | Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction. Circulation, 2020, 142, 1725-1735. | 1.6 | 77 |
| 36 | Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 e016573. | 1.6 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The MARBLE Study Protocol: Modulating ApoE Signaling to Reduce Brain Inflammation, DeLirium, and PostopErative Cognitive Dysfunction. Journal of Alzheimer's Disease, 2020, 75, 1319-1328. | 1.2 | 11 |
| 38 | Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting. Therapeutic Innovation and Regulatory Science, 2020, 54, 1477-1488. | 0.8 | 11 |
| 39 | A Framework for Safety Evaluation Throughout the Product Development Life-Cycle. Therapeutic Innovation and Regulatory Science, 2020, 54, 821-830. | 0.8 | 7 |
| 40 | Initial Invasive or Conservative Strategy for Stable Coronary Disease. New England Journal of Medicine, 2020, 382, 1395-1407. | 13.9 | 1,508 |
| 41 | Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006399. | 0.9 | 23 |
| 42 | Design and analytic considerations for using patient-reported health data in pragmatic clinical trials: report from an NIH Collaboratory roundtable. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 634-638. | 2.2 | 10 |
| 43 | Sex-Specific Risks of MajorÂCardiovascular and LimbÂEventsÂinÂPatients With Symptomatic Peripheral Artery Disease. Journal of the American College of Cardiology, 2020, 75, 608-617. | 1.2 | 30 |
| 44 | Time for NIH to lead on data sharing. Science, 2020, 367, 1308-1309. | 6.0 | 42 |
| 45 | Pragmatic Randomized Trials Using Claims or Electronic Health Record Data. , 2020, , 1-11. | | 4 |
| 46 | University of Pennsylvania 11th annual conference on statistical issues in clinical trials: Estimands, missing data and sensitivity analysis (morning panel session). Clinical Trials, 2019, 16, 350-362. | 0.7 | 3 |
| 47 | Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial. Vascular Medicine, 2019, 24, 422-430. | 0.8 | 13 |
| 48 | Open science: The open clinical trials data journey. Clinical Trials, 2019, 16, 539-546. | 0.7 | 24 |
| 49 | Impact of Procedural Bleeding in Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2019, 12, e008069. | 1.4 | 6 |
| 50 | Acute Limb Ischemia in Peripheral Artery Disease. Circulation, 2019, 140, 556-565. | 1.6 | 80 |
| 51 | P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. JAMA Cardiology, 2019, 4, 680. | 3.0 | 9 |
| 52 | Stroke in Patients With Peripheral Artery Disease. Stroke, 2019, 50, 1356-1363. | 1.0 | 33 |
| 53 | Natural History and Outcomes of Patients with Critical Limb Ischemia in the Euclid Trial. European Journal of Vascular and Endovascular Surgery, 2019, 58, e117-e118. | 0.8 | 0 |
| 54 | Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease. JAMA Cardiology, 2019, 4, 7. | 3.0 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. European Journal of Vascular and Endovascular Surgery, 2018, 55, 109-117. | 0.8 | 28 |
| 56 | Transforming the future of health together: The <scp>Learning Health Systems Consensus Action Plan</scp>. Learning Health Systems, 2018, 2, e10055. | 1.1 | 17 |
| 57 | Cardiovascular and Limb Outcomes in Patients With Diabetes and PeripheralÂArtery Disease. Journal of the American College of Cardiology, 2018, 72, 3274-3284. | 1.2 | 64 |
| 58 | Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease. JAMA Network Open, 2018, 1, e185239. | 2.8 | 68 |
| 59 | Cardiovascular Outcomes After LowerÂExtremity Endovascular or SurgicalÂRevascularization. Journal of the American College of Cardiology, 2018, 72, 1563-1572. | 1.2 | 39 |
| 60 | Finding Means to Fulfill the Societal and Academic Imperative for Open Data Access and Sharing. JAMA Cardiology, 2018, 3, 793. | 3.0 | 5 |
| 61 | Deriving Real-World Insights From Real-World Data: Biostatistics to the Rescue. Annals of Internal Medicine, 2018, 169, 401. | 2.0 | 9 |
| 62 | Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vascular Medicine, 2018, 23, 523-530. | 0.8 | 29 |
| 63 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet, The, 2017, 389, 1799-1808. | 6.3 | 174 |
| 64 | Comments on â€˜Estimands in clinical trials â€“ broadening the perspectiveâ€™. Statistics in Medicine, 2017, 36, 24-26. | 0.8 | 0 |
| 65 | Statistical controversies in clinical research: data access and sharingâ€”can we be more transparent about clinical research? Letâ€™s do whatâ€™s right for patients. Annals of Oncology, 2017, 28, 1734-1737. | 0.6 | 5 |
| 66 | Data Sharing at a Crossroads. New England Journal of Medicine, 2016, 375, 1115-1117. | 13.9 | 49 |
| 67 | SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2015, 38, 506-14. | 0.6 | 114 |
| 68 | Bumps and bridges on the road to responsible sharing of clinical trial data. Clinical Trials, 2014, 11, 7-12. | 0.7 | 27 |
| 69 | Access to Patient-Level Data from GlaxoSmithKline Clinical Trials. New England Journal of Medicine, 2013, 369, 475-478. | 13.9 | 112 |
| 70 | SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Annals of Internal Medicine, 2013, 158, 200. | 2.0 | 4,463 |
| 71 | 10â€‰Years with ICH E10: Choice of Control Groups. Pharmaceutical Statistics, 2011, 10, 407-409. | 0.7 | 4 |
| 72 | Statisticians in the Pharmaceutical Industry: The 21st Century. Statistics in Biopharmaceutical Research, 2010, 2, 145-152. | 0.6 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Public disclosure of clinical research. Lancet, The, 2009, 373, 1319-1320. | 6.3 | 8 |
| 74 | ICH-E9 reflections and considerations. Pharmaceutical Statistics, 2008, 7, 233-235. | 0.7 | 5 |
| 75 | Reporting the findings of clinical trials: a discussion paper. Bulletin of the World Health Organization, 2008, 2008, 492-493. | 1.5 | 30 |
| 76 | The GSK Clinical Study Results Database: Site Utilization Metrics for a Large Public Database. Drug Information Journal, 2008, 42, 247-252. | 0.5 | 0 |
| 77 | Electronic Health Records, Medical Research, and the Tower of Babel. New England Journal of Medicine, 2008, 358, 1738-1740. | 13.9 | 79 |
| 78 | Trial summaries on results databases and journal publication. Lancet, The, 2006, 367, 1635-1636. | 6.3 | 9 |
| 79 | Reasons for optimism not disillusionment. Journal of the Royal Society of Medicine, 2006, 99, 435-435. | 1.1 | 2 |
| 80 | Requiring â€˜independentâ€™ statistical analyses for industry sponsored trials?. Pharmaceutical Statistics, 2006, 5, 5-6. | 0.7 | 5 |
| 81 | Clinical Trials Registration. PLoS Medicine, 2006, 3, e157. | 3.9 | 4 |
| 82 | The Society for Clinical Trials opposes US legislation to permit marketing of unproven medical therapies for seriously ill patients. Clinical Trials, 2006, 3, 154-157. | 0.7 | 18 |
| 83 | Trial Registration: Ignored to Irresistible. JAMA - Journal of the American Medical Association, 2005, 293, 158. | 3.8 | 1 |
| 84 | The Society for Clinical Trials supports United States legislation mandating trials registration. Clinical Trials, 2005, 2, 193-193. | 0.7 | 1 |
| 85 | More on compulsory registration of clinical trials: GSK has created useful register. BMJ: British Medical Journal, 2005, 330, 479.3-480. | 2.4 | 9 |
| 86 | Liability issues for data monitoring committee members. Clinical Trials, 2004, 1, 525-531. | 0.7 | 37 |
| 87 | Issues in regulatory guidelines for data monitoring committees. Clinical Trials, 2004, 1, 162-169. | 0.7 | 21 |
| 88 | Industry perspectives on ICH guidelines. Statistics in Medicine, 2002, 21, 2949-2957. | 0.8 | 7 |
| 89 | Strategic use of statistical thinking in drug development. Statistics in Medicine, 2000, 19, 3211-3217. | 0.8 | 8 |
| 90 | Guidelines for Quality Assurance in Multicenter Trials. Contemporary Clinical Trials, 1998, 19, 477-493. | 2.0 | 106 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | An approach to the assessment of therapeutic drug interactions with fixed combination drug products. Journal of Biopharmaceutical Statistics, 1996, 6, 231-240. | 0.4 | 8 |
| 92 | Data monitoring and interim analyses in the pharmaceutical industry: Ethical and logistical considerations. Statistics in Medicine, 1993, 12, 471-479. | 0.8 | 16 |
| 93 | Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Critical Care Medicine, 1993, 21, 19-30. | 0.4 | 163 |
| 94 | Cimetidine 800 mg Twice Daily for Healing Erosions and Ulcers in Gastroesophageal Reflux Disease. Journal of Clinical Gastroenterology, 1990, 12, S29-S34. | 1.1 | 25 |
| 95 | Comparison of Cimetidine and Placebo for the Prophylaxis of Upper Gastrointestinal Bleeding Due to Stress-related Gastric Mucosal Damage in the Intensive Care Unit. Journal of Intensive Care Medicine, 1990, 5, 26-32. | 1.3 | 44 |
| 96 | Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. Clinical Pharmacology and Therapeutics, 1989, 46, 208-218. | 2.3 | 16 |
| 97 | Comparison between continuous and intermittent infusion regimens of cimetidine in ulcer patients. Clinical Pharmacology and Therapeutics, 1989, 46, 234-239. | 2.3 | 8 |
| 98 | Monitoring versus interim analysis of clinical trials: A perspective from the pharmaceutical industry. Contemporary Clinical Trials, 1989, 10, 57-70. | 2.0 | 26 |
| 99 | Clinical Pharmacokinetics of Pinacidil, A Potassium Channel Opener, in Hypertension. Journal of Clinical Pharmacology, 1989, 29, 33-40. | 1.0 | 11 |
| 100 | Vasodilator monotherapy in the treatment of hypertension: Comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin. Clinical Pharmacology and Therapeutics, 1988, 44, 78-92. | 2.3 | 24 |
| 101 | Cellular Electrophysiology of Clofilium, a New Antifibrillatory Agent, in Normal and Ischemic Canine Purkinje Fibers. Journal of Cardiovascular Pharmacology, 1981, 3, 881-895. | 0.8 | 29 |
| 102 | Understanding Study Drug Discontinuation Through EUCLID. Frontiers in Cardiovascular Medicine, 0, 9, . | 1.1 | 2 |